EULAV Asset Management Sells 9,000 Shares of Insmed, Inc. $INSM

EULAV Asset Management lowered its position in Insmed, Inc. (NASDAQ:INSM) by 10.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 81,000 shares of the biopharmaceutical company’s stock after selling 9,000 shares during the period. EULAV Asset Management’s holdings in Insmed were worth $14,097,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. CIBC Private Wealth Group LLC increased its position in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares in the last quarter. CoreCap Advisors LLC bought a new stake in Insmed during the 4th quarter worth approximately $27,000. SBI Securities Co. Ltd. increased its stake in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares in the last quarter. GraniteShares Advisors LLC bought a new stake in Insmed during the 4th quarter worth approximately $30,000. Finally, RiverPark Advisors LLC bought a new stake in Insmed during the 3rd quarter worth approximately $38,000.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on INSM shares. Royal Bank Of Canada lowered their target price on Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research note on Friday. Stifel Nicolaus increased their target price on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Raymond James Financial started coverage on Insmed in a research note on Friday, April 10th. They set an “outperform” rating and a $200.00 target price for the company. Roth Mkm reissued a “buy” rating and set a $212.00 target price on shares of Insmed in a research note on Friday, April 17th. Finally, Mizuho increased their target price on Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $210.50.

Insmed Trading Down 10.2%

NASDAQ:INSM opened at $94.22 on Friday. Insmed, Inc. has a twelve month low of $70.57 and a twelve month high of $212.75. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The business has a 50 day moving average price of $130.45 and a two-hundred day moving average price of $154.95. The company has a market cap of $20.42 billion, a P/E ratio of -16.39 and a beta of 0.79.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the prior year, the firm posted ($1.42) EPS. The business’s revenue was up 229.7% on a year-over-year basis. As a group, analysts expect that Insmed, Inc. will post -2.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In other Insmed news, COO Roger Adsett sold 88,060 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at $17,584,130.30. This represents a 45.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Alexander Smith sold 19,638 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the transaction, the insider directly owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. This trade represents a 27.46% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 160,482 shares of company stock worth $24,438,193. Insiders own 2.10% of the company’s stock.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.